A frontline chemotherapy-free strategy using a tyrosine kinase inhibitor and immunotherapy beats the conventional chemotherapy approach for treating Philadelphia-positive acute lymphoblastic leukaemia ...

Brentuximab vedotin (Adcetris, Takeda) is now on the PBS as part of the multi-drug BrECADD chemotherapy regimen for front-line treatment in adult patients with advanced stage CD30+ Hodgkin lymphoma.

JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

The addition of the bispecific T-cell engager tarlatamab to durvalumab as first-line maintenance therapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).

SGLT2 inhibitor use in patients with cardiovascular disease, diabetes, heart failure, and/or chronic kidney disease is associated with small but statistically significant and consistent increases in ...

Trials of agents for the management of IgA nephropathy dominated the American Society of Nephrology’s 2026 Kidney Week, including three featured as high-impact trials in the opening plenary and four ...

PCOS is likely to need another rebrand in the near future because its new name, PMOS, is scientifically inaccurate, it is being argued. A debate over the future name of polycystic ovary syndrome has ...

Young adults who had repeated courses of antibiotics from childhood onwards are more likely to have irritable bowel syndrome by age 24, with the odds rising as their antibiotic exposure increased, ...

The image of the wise and skilful healer has driven countless clinicians to dedicate their lives to the profession, but that ...

Internal medicine specialists remain among the highest paid professionals in Australia, although average earnings continue to vary widely depending on specialty and gender, new data from the ...

Apixaban reduces bleeding in acute venous thromboembolism (VTE) by more than 50%, compared to rivaroxaban, data presented at the ISTH 2025 congress shows. Results from the COBRRA trial showed that 3% ...